Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hidekazu Shirota

Showing results (61-70 of 90) with videos related to

Pageof 9
Sort By:
Cancer Science|January 5, 2025
Comprehensive Genome Profiling-Initiated Tumor-Informed Circulating Tumor DNA Monitoring for Patients With Advanced CancerTaiga Sasaki, Hayato Hiraki, Akiko Yashima-Abo, et al.
Cancer Management and Research|October 2, 2018
Predictive factors for the efficacy of the second taxane treatment in patients with advanced cancerHiroo Imai, Ken Saijo, Keigo Komine, et al.
Chemotherapy|April 5, 2016
Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell CarcinomaHiroo Imai, Keigo Komine, Shin Takahashi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 19, 2013
β-Defensin 2 and 3 promote the uptake of self or CpG DNA, enhance IFN-α production by human plasmacytoid dendritic cells, and promote inflammationPoonam Tewary, Gonzalo de la Rosa, Neeraj Sharma, et al.
Internal Medicine (Tokyo, Japan)|June 12, 2024
Correlation between Efficacy and Cardiovascular Adverse Events in Patients with Advanced Solid Cancer Who Received VEGF Pathway Inhibitors: Hypertension within the First Eight Weeks Is Associated with Favorable Outcomes of Patients Treated with VEGF Pathway InhibitorsYuya Yoshida, Masanobu Takahashi, Keigo Komine, et al.
Internal Medicine (Tokyo, Japan)|March 18, 2016
Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau DiseaseAkihiro Kobayashi, Masanobu Takahashi, Hiroo Imai, et al.
International Cancer Conference Journal|March 31, 2025
Coexisting germline variants of <i>MLH1</i> and <i>MSH6</i> in a patient with Lynch syndrome who had uterine and ovarian cancerSho Umegaki, Masanobu Takahashi, Junko Hasegawa-Minato, et al.
International Journal of Clinical Oncology|April 27, 2026
Association between antibiotic use, immune-related adverse events, and efficacy of immunotherapy in esophageal squamous cell carcinomaTomoaki Shirakawa, Hiroo Imai, Ken Saijo, et al.
Cancer Management and Research|April 4, 2022
Antibiotic Treatment Improves the Efficacy of Oxaliplatin-Based Therapy as First-Line Chemotherapy for Patients with Advanced Gastric Cancer: A Retrospective StudyHiroo Imai, Ken Saijo, Keigo Komine, et al.
Cancer Science|July 7, 2026
Phase II Trial of Nivolumab in Advanced Solid Tumors Based on Genomic Profiling: BELIEVE Trial (NCCH1901) SubcohortMasashi Kanai, Kuniko Sunami, Tatsunori Shimoi, et al.
Pageof 9

Showing results (61-70 of 90) with videos related to

Sort By:
Pageof 9
Cancer Science|January 5, 2025
Comprehensive Genome Profiling-Initiated Tumor-Informed Circulating Tumor DNA Monitoring for Patients With Advanced CancerTaiga Sasaki, Hayato Hiraki, Akiko Yashima-Abo, et al.
Cancer Management and Research|October 2, 2018
Predictive factors for the efficacy of the second taxane treatment in patients with advanced cancerHiroo Imai, Ken Saijo, Keigo Komine, et al.
Chemotherapy|April 5, 2016
Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell CarcinomaHiroo Imai, Keigo Komine, Shin Takahashi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 19, 2013
β-Defensin 2 and 3 promote the uptake of self or CpG DNA, enhance IFN-α production by human plasmacytoid dendritic cells, and promote inflammationPoonam Tewary, Gonzalo de la Rosa, Neeraj Sharma, et al.
Internal Medicine (Tokyo, Japan)|June 12, 2024
Correlation between Efficacy and Cardiovascular Adverse Events in Patients with Advanced Solid Cancer Who Received VEGF Pathway Inhibitors: Hypertension within the First Eight Weeks Is Associated with Favorable Outcomes of Patients Treated with VEGF Pathway InhibitorsYuya Yoshida, Masanobu Takahashi, Keigo Komine, et al.
Internal Medicine (Tokyo, Japan)|March 18, 2016
Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau DiseaseAkihiro Kobayashi, Masanobu Takahashi, Hiroo Imai, et al.
International Cancer Conference Journal|March 31, 2025
Coexisting germline variants of <i>MLH1</i> and <i>MSH6</i> in a patient with Lynch syndrome who had uterine and ovarian cancerSho Umegaki, Masanobu Takahashi, Junko Hasegawa-Minato, et al.
International Journal of Clinical Oncology|April 27, 2026
Association between antibiotic use, immune-related adverse events, and efficacy of immunotherapy in esophageal squamous cell carcinomaTomoaki Shirakawa, Hiroo Imai, Ken Saijo, et al.
Cancer Management and Research|April 4, 2022
Antibiotic Treatment Improves the Efficacy of Oxaliplatin-Based Therapy as First-Line Chemotherapy for Patients with Advanced Gastric Cancer: A Retrospective StudyHiroo Imai, Ken Saijo, Keigo Komine, et al.
Cancer Science|July 7, 2026
Phase II Trial of Nivolumab in Advanced Solid Tumors Based on Genomic Profiling: BELIEVE Trial (NCCH1901) SubcohortMasashi Kanai, Kuniko Sunami, Tatsunori Shimoi, et al.
Pageof 9